Synthesis, preclinical and pharmacokinetic evaluation of a new zoledronate derivative as a promising antiosteoporotic candidate using radiolabeling technique
A novel zoledronic acid (ZL) derivative, 3‐(2‐ethyl‐4‐methyi‐1H‐imidazole‐1‐yl)‐1‐hydroxy‐1‐phosphonopropyl phosphonic acid (EMIHPBP), was synthesized, characterized and successfully radiolabeled with 99mTc. The in‐vivo biodistribution of 99mTc‐EMIHPBP was investigated and compared with the previously reported zoledronate derivatives aiming to formulate a novel zoledronate derivative with a high potential uptake to bone as a promising antiosteoporotic candidate. In order to further evaluate the bone uptake efficiency, the pharmacokinetics of 99mTc‐EMIHPBP was investigated, and showed that maxi...
Source: Journal of Labelled Compounds and Radiopharmaceuticals - June 15, 2017 Category: Biochemistry Authors: H.A. Motaleb, I.T. Ibrahim, M. El ‐Tawoosy, M.I. Mohamed Tags: RESEARCH ARTICLE Source Type: research

Re: Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients with Bone Metastases: A Randomized Clinical Trial
A. L. Himelstein, J. C. Foster, J. L. Khatcheressian, J. D. Roberts, D. K. Seisler, P. J. Novotny, R. Qin, R. S. Go, S. S. Grubbs, T. O ’Connor, M. R. Velasco, Jr., D. Weckstein, A. O’Mara, C. L. Loprinzi and C. L. Shapiro (Source: The Journal of Urology)
Source: The Journal of Urology - June 14, 2017 Category: Urology & Nephrology Authors: Samir S. Taneja Tags: Urological Survey Source Type: research

Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer
. (Source: OncoImmunology)
Source: OncoImmunology - June 14, 2017 Category: Cancer & Oncology Authors: Dhifaf Sarhan Caroline Leijonhufvud Shannon Murray Kristina Witt Christina Seitz Majken Wallerius Hanjing Xie Anders Ull én Ulrika Harmenberg Elisabet Lidbrink Charlotte Rolny John Andersson Andreas Lundqvist Source Type: research

Comparison Table: Drugs for Postmenopausal Osteoporosis (online only)
Date: June 19, 2017 Issue #:  1523Summary:  View the Comparison Table: Drugs for Postmenopausal Osteoporosis (Source: The Medical Letter)
Source: The Medical Letter - June 12, 2017 Category: Drugs & Pharmacology Authors: admin Tags: abaloparatide Actonel Alendronate Atelvia bazedoxifene Binosto Boniva Denosumab Duavee Estrogens Evista Forteo Fosamax Ibandronate Miacalcin Osteoporosis Postmenopausal osteoporosis Prolia Raloxifene Reclast risedro Source Type: research

The Association between Fever and Prognosis in Lung Cancer Patients with Bone Metastases Receiving Zoledronic Acid
Zoledronic acid is an established agent used in the management of metastatic bone disease. The administration of zoledronic acid improves overall survival (OS) of lung cancer patients with bone metastases receiving chemotherapy. However, it is currently unknown whether zoledronic acid-induced fever is associated with OS. The purpose of this study was to examine the association between zoledronic acid-induced fever and prognosis in lung cancer patients with bone metastases. We retrospectively analyzed 98 lung cancer patients with bone metastases who had received zoledronic acid. The end point outcome measure was OS. Multiva...
Source: Chemotherapy - June 12, 2017 Category: Cancer & Oncology Source Type: research

Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures
(Source: Osteoporosis International)
Source: Osteoporosis International - June 6, 2017 Category: Orthopaedics Source Type: research

Potential chemotherapeutic effects of Diosgenin, zoledronic acid and Epigallocatechin-3-gallate on PE/CA-PJ15 oral squamous cancer cell line
(Source: Archives of Oral Biology)
Source: Archives of Oral Biology - June 6, 2017 Category: Dentistry Authors: Eduardo Pons-Fuster L ópez, Qin-tong Wang, Wei Wei, Pia López Jornet Tags: Research Paper Source Type: research

Effects of Local and Systemic Zoledronic Acid Application on Titanium Implant Osseointegration: An Experimental Study Conducted on Two Surface Types
Abstract: The aim of this study was to evaluate the effects of local and systemic zoledronic acid (ZA) applications on titaniumoksit ceramic blasted (TiO-CB)- and sandblasted large acid-grit (SLA)-surfaced titanium implant osseointegration. Twelve New Zealand White rabbits were used in the study, divided into 6 groups: the TiO-CB (TiO-CB-CNT) (n = 2) and SLA (SLA-CNT) (n = 2) control groups in which TiO-CB- and SLA-surfaced titanium implants were surgically inserted into rabbit tibias but no treatment was applied; the TiO-CB (TiO-CB-LZA) (n = 2) and SLA (SLA-LZA) (n = 2) local ZA groups in which 1 mL of nor...
Source: Journal of Craniofacial Surgery - June 1, 2017 Category: Surgery Tags: Original Articles Source Type: research

Erratum to: Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan
(Source: Osteoporosis International)
Source: Osteoporosis International - June 1, 2017 Category: Orthopaedics Source Type: research

Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial
ConclusionsA single dose of dexamethasone 4  mg does not influence the incidence or severity of APR following first exposure to ZOL.Trial registrationACTRN12615000794505 (Source: Osteoporosis International)
Source: Osteoporosis International - June 1, 2017 Category: Orthopaedics Source Type: research

Effect of Time of Administration of Teriparatide on Bone Mineral Density in Glucocorticoid-Induced Osteoporosis
Teriparatide (TPTD) (recombinant DNA origin human parathormone [1 –34]) is approved for the treatment of glucocorticoid-induced osteoporosis (GIO). There are reports of factors that affect the response to TPTD in GIO treatment. This work describes the case of a 71-yr-old woman diagnosed with lupus nephropathy treated with 40 mg/d of meprednisone, and who suffe red multiple vertebral fractures. Despite treatment with a single 5 mg dose of zoledronic acid, the patient continued to have vertebral fractures. (Source: Journal of Clinical Densitometry)
Source: Journal of Clinical Densitometry - June 1, 2017 Category: Radiology Authors: Silvina R. Mastaglia Tags: Case Report Source Type: research

Zoledronic acid and alendronate sodium and the implications in orthodontic movement
ConclusionAlendronate sodium and zoledronic acid have similar effects on the periodontal tissue during orthodontic treatment in rats. Especially, zoledronic acid can affect orthodontic tooth movement. (Source: Orthodontics and Craniofacial Research)
Source: Orthodontics and Craniofacial Research - June 1, 2017 Category: Dentistry Authors: J. S. Franzoni, F. M. P. Soares, E. Zaniboni, M. Vedovello Filho, M. P. Santamaria, G. M. T. Santos, M. A. M. Esquisatto, M. Felonato, F. A. S. Mendonca, C. M. Franzini, M. Santamaria Tags: ORIGINAL ARTICLE Source Type: research

Immune-mediated syndromes following intravenous bisphosphonate therapy
ConclusionsIntravenous ABP may trigger induction of persistent autoimmune syndromes, especially when accompanied by an immediate adverse reaction or pre-existing malignancy. (Source: Inflammopharmacology)
Source: Inflammopharmacology - May 31, 2017 Category: Drugs & Pharmacology Source Type: research

Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a pilot study
Summary AimsThe pilot study was designed to evaluate the early effect of intravenous (iv) zoledronic acid (ZA) on renal function. MethodsFive mg iv ZA was administered to 23 patients with osteoporosis (17 women and 6 men, mean age 73±7 SD years). Urinary NGAL, KIM‐1, and MCP‐1, plasma (p) MCP‐1 and serum (s) IL‐18, serum calcium (sCa), Creatinine clearance (CrCl), parathyroid hormone (PTH), plasma C‐terminal FGF23 (pFGF23), serum (s) Klotho, calcium excretion (CaEx) and renal threshold phosphate concentration/GFR (TmPO4/GFR) were assessed at baseline, 24 hours (h) and day (d) 30 after administration. Resul...
Source: British Journal of Clinical Pharmacology - May 25, 2017 Category: Drugs & Pharmacology Authors: C. Cipriani, J. Pepe, C. Clementelli, R. Manai, L. Colangelo, V. Fassino, L. Nieddu, S. Minisola Tags: HUMAN TOXICOLOGY Source Type: research

The role of 18F-FDG PET/CT in early detection and risk assessment of medication-related osteonecrosis of the jaw
305Objectives: Medication-related osteonecrosis of the jaw (MRONJ) is a significant side effect of antiresorptive and antiangiogenic drugs prescribed for advanced cancer patients. Because MRONJ is intractable, the early detection and risk assessment before the development of stage 2 MRONJ are crucial and have been attempted by various methods. However, the role of 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET)/computed tomography (CT) in the early detection and risk assessment of MRONJ is not yet fully understood. The aim of this study was to validate a diagnostic ability of FDG PET/CT for early-stage MRON...
Source: Journal of Nuclear Medicine - May 24, 2017 Category: Nuclear Medicine Authors: Watanabe, S., Nakajima, K., Inokuchi, M., Noguchi, N., Kawashiri, S., Mizokami, A., Kinuya, S. Tags: Musculoskeletal Source Type: research

DOTAZOLand NODAGAZOL for theranostics of bone metastases
Conclusion: The Ga-68-labeled NODAGA based zoledronic acid derivative NODAGAZOL shows quantitative labeling and does not require subsequent purification. Both Ga-68-NODAGAZOL and Ga-68-DOTAZOL exhibit high bone accumulation, low uptake in soft tissue and fast renal clearance. Bone accumulation was higher for NODAGAZOL compared to DOTAZOL, which matches the experimental data obtained earlier for Ga-68-NO2APBP vs. Ga-68-BPAMD. Considering the potential of DOTAZOL for endoradiotherapy with Lu-177, Ga-68-NODAGAZOL appears to become the diagnostic arm for the theranostic pair for bone metastases. Research Support: (Source: Jour...
Source: Journal of Nuclear Medicine - May 24, 2017 Category: Nuclear Medicine Authors: Pfannkuchen, N., Bergmann, R., Pietzsch, J., Bachmann, M., Roesch, F. Tags: Radiotherapy and Monitoring Therapy Source Type: research

Zoledronic acid renders human M1 and M2 macrophages susceptible to V δ2 + γδ T cell cytotoxicity in a perforin-dependent manner
In this study we focussed on macrophages (M ϕs), as these cells have been shown to take up ZA. We differentiated peripheral blood monocytes from healthy donors into Mϕs and then treated them with IFN-γ or IL-4 to generate M1 and M2 Mϕs, respectively. We characterised these Mϕs based on their phenotype and cytokine production and then te sted whether ZA rendered them susceptible to Vδ2+ T cell cytotoxicity. Consistent with the literature, IFN- γ-treated Mϕs expressed higher levels of the M1 markers CD64 and IL-12p70, whereas IL-4-treated Mϕs expressed higher levels of the M2 markers CD206 and ch...
Source: Cancer Immunology, Immunotherapy - May 13, 2017 Category: Cancer & Oncology Source Type: research

Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases
AbstractPurposeDenosumab reduces the incidence of skeletal-related events (SREs) in solid tumor patients with bone metastases (BM). However, there have been no detailed reports of the efficacy of denosumab in untreated non-squamous non-small cell lung cancer (NSCLC) patients with BM.MethodsThe medical records of patients with untreated non-squamous NSCLC and BM at diagnosis at our institution were reviewed retrospectively. The overall survival (OS) and the time to SREs were analyzed according to the treatment for the BM.ResultsOf the total of 149 patients who were eligible, 52 had received denosumab (Dmab group), 51 had re...
Source: Journal of Cancer Research and Clinical Oncology - May 12, 2017 Category: Cancer & Oncology Source Type: research

Evidence-based prevention and treatment of osteoporosis after spinal cord injury: a systematic review
ConclusionsNo recommendations can be made from this review, regarding overall low quality of evidence as a result of high risk of bias, low sample size in most of the studies, and notable heterogeneity in type of intervention, outcome measurement, and duration of treatment. Therefore, future high-quality RCT studies with higher sample sizes and more homogeneity are strongly recommended to provide high-quality evidence and make applicable recommendations for prevention and treatment of SCI-related bone loss. (Source: European Spine Journal)
Source: European Spine Journal - May 11, 2017 Category: Orthopaedics Source Type: research

Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells.
In conclusion, demonstrating that NZ is capable to inhibit the cross talk between MSCs and PCa, this study provides a novel insight to explain the powerful anticancer activity of NZ on PCa. PMID: 28477013 [PubMed - as supplied by publisher] (Source: Oncotarget)
Source: Oncotarget - May 10, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
CONCLUSIONS: Compared with zoledronic acid, denosumab provides a cost-effective treatment option for the prevention of SREs in patients with prostate cancer, breast cancer, and OST in the Czech Republic. PMID: 28485692 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - May 10, 2017 Category: Health Management Tags: J Med Econ Source Type: research

Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update from the American College of Physicians.
Abstract Description: This guideline updates the 2008 American College of Physicians (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women. This guideline is endorsed by the American Academy of Family Physicians. Methods: The ACP Clinical Guidelines Committee based these recommendations on a systematic review of randomized controlled trials; systematic reviews; large observational studies (for adverse events); and case reports (for rare events) that were published between 2 January 2005 and 3 June 2011. The review was updated to July 2016 by using a mach...
Source: Annals of Internal Medicine - May 9, 2017 Category: Internal Medicine Authors: Qaseem A, Forciea MA, McLean RM, Denberg TD, Clinical Guidelines Committee of the American College of Physicians Tags: Ann Intern Med Source Type: research

In vivo distribution of zoledronic acid in a bisphosphonate-metal complex-based nanoparticle formulation synthesized by a reverse microemulsion method
Publication date: 30 June 2017 Source:International Journal of Pharmaceutics, Volume 526, Issues 1–2 Author(s): Xu Li, Youssef W. Naguib, Zhengrong Cui Bisphosphonates are used to treat bone diseases such as osteoporosis and cancer-induced bone pain and fractures. It is thought that modifying the pharmacokinetics and biodistribution profiles of bisphosphonates (i.e. rapid renal clearance and extensive bone absorption) will not only reduce their side effects, but also expand their clinical applications to extraskeletal tissues. In the present work, using zoledronic acid (Zol) and calcium as model bisphosphonate and m...
Source: International Journal of Pharmaceutics - May 4, 2017 Category: Drugs & Pharmacology Source Type: research

Could γ/δ T cells explain adverse effects of zoledronic acid? Comment on the article by Reinhardt et al
(Source: Arthritis and Rheumatism)
Source: Arthritis and Rheumatism - May 3, 2017 Category: Rheumatology Authors: Cristian Caimmi, Maurizio Rossini, Ombretta Viapiana, Luca Idolazzi, Giovanni Adami, Davide Gatti Tags: Letter Source Type: research

Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta
In this study, we examined the therapeutic potential of anti-Sclerostin Antibody (Scl-Ab) and bisphosphonate treatments for the bone fragility disorder Osteogenesis Imperfecta (OI). Mice with the Amish OI mutation (Col1a2 G610C mice) and control wild type littermates (WT) were treated from week 5 to week 9 of life with (1) saline (control), (2) zoledronic acid given 0.025mg/kg s.c. weekly (ZA), (3) Scl-Ab given 50mg/kg IV weekly (Scl-Ab), or (4) a combination of both (Scl-Ab/ZA). Functional outcomes were prioritized and included bone mineral density (BMD), bone microarchitecture, long bone bending strength, and vertebral c...
Source: Bone - April 28, 2017 Category: Orthopaedics Authors: David G. Little, Lauren Peacock, Kathy Mikulec, Michaela Kneissel, Ina Kramer, Tegan L. Cheng, Aaron Schindeler, Craig Munns Tags: Full Length Article Source Type: research

Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States
This study examined real-world long-term use of guideline-recommended bone targeted agents (BTA) among patients with metastatic solid tumors.MethodsAdults with a solid tumor diagnosis followed by a bone metastasis diagnosis in 2012 –2014 were identified from electronic medical records in the Oncology Services Comprehensive Electronic Records (OSCER) database. Patients initiated zoledronic acid (ZA) or denosumab on or after the bone metastasis diagnosis and were followed through last clinic visit by 30 June 2015. We describe time to BTA initiation, compliance (≥12 administrations in a year), switching, and non-pers...
Source: Supportive Care in Cancer - April 25, 2017 Category: Cancer & Oncology Source Type: research

Primary signet cell carcinoma of the prostate: a  case report
SummaryPrimary signet cell carcinoma of the prostate is very rare histological variant and usually originates from the stomach, colon, and pancreas. This malignancy was first reported in 1979 and there have been case series with small numbers of patients and case reports in the literature. Signet cell carcinoma of the prostate has a poor outcome when compared to classic prostate adenocarcinoma. A  case of primary signet cell carcinoma of the prostate that was treated with maximal androgen deprivation therapy with zoledronic acid is reported. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 25, 2017 Category: Cancer & Oncology Source Type: research

Two isomorphous Co(II) coordination polymers based on new [small alpha],[small alpha]-disubstituted derivatives of zoledronic acid: synthesis, structures and properties
Dalton Trans., 2017, Accepted Manuscript DOI: 10.1039/C7DT00410A, PaperTomasz Rojek, Waldemar Goldeman, Katarzyna Slepokura, Marek Duczmal, Agnieszka Wojciechowska, Ewa Matczak-Jon Two novel [small alpha],[small alpha]-disubstituted derivatives of zoledronic acid, namely 1-hydroxy-2-(1H-imidazol-1-yl)-2-methylpropylidene-1,1-diphosphonic acid (H4L1) and 1-hydroxy-2-[1-(1H-imidazol-1-yl)cyclopropyl]ethylidene-1,1-diphosphonic acid (H4L2) were synthesized and structurally characterized by single-crystal X-ray diffraction. The reaction of cobalt acetate with... The content of this RSS Feed (c) The Royal Society of Chemistry (...
Source: RSC - Dalton Trans. latest articles - April 24, 2017 Category: Chemistry Authors: Tomasz Rojek Source Type: research

Evaluation of the combined use of metronomic zoledronic acid and Coriolus versicolor in intratibial breast cancer mouse model
Conclusions These findings suggested that combination treatment of CV and mZOL attenuated breast tumor propagation, protected against osteolytic bone lesion without significant metastases. This study provides scientific evidences on the beneficial outcome of using CV together with mZOL in the management of breast cancer and metastasis, which may lead to the development of CV as adjuvant health supplement for the control of breast cancer. Graphical abstract (Source: Journal of Ethnopharmacology)
Source: Journal of Ethnopharmacology - April 20, 2017 Category: Drugs & Pharmacology Source Type: research

Cytoprotective effects of melatonin on zoledronic acid-treated human osteoblasts
Conclusions MLT has a cytoprotective effect on ZA-treated human osteoblasts and could represent a promising preventative alternative for patients at risk of bisphosphonate-related osteonecrosis of the jaw. (Source: Journal of Cranio Maxillofacial Surgery)
Source: Journal of Cranio Maxillofacial Surgery - April 19, 2017 Category: ENT & OMF Source Type: research

Cytoprotective effects of melatonin on zoledronic acid-treated human osteoblasts
To evaluate the cytoprotective effects of melatonin (MLT) on zoledronic acid (ZA)-treated human osteoblasts. (Source: Journal of Cranio-Maxillofacial Surgery)
Source: Journal of Cranio-Maxillofacial Surgery - April 18, 2017 Category: ENT & OMF Authors: F. Camacho-Alonso, I. Urrutia-Rodr íguez, D. Oñate-Cabrerizo, R.E. Oñate-Sánchez, F.J. Rodríguez-Lozano Source Type: research

Wenshen Zhuanggu formula effectively suppresses breast cancer bone metastases in a mouse Xenograft model.
In this study we investigated the efficacy of WSZG in preventing bone metastases and the potential mechanisms in a mouse xenograft model of breast cancer bone metastases. This model was established by injection of human MDA-MB-231BO-Luc breast cancer cells alone or a mixture of the cancer cells with bone marrow-derived mesenchymal stem cells (BMSCs) into left ventricle of the heart in female nude mice. Then the mice were treated with WSZG (3.25, 6.5 or 13.0 mg·kg(-1)·d(-1), ig) for four weeks, whereas zoledronic acid (100 μg/kg per week, ig) was used as a positive control. The occurrence and development of...
Source: Acta Pharmacologica Sinica - April 17, 2017 Category: Drugs & Pharmacology Authors: Li JJ, Chen WL, Wang JY, Hu QW, Sun ZP, Zhang S, Liu S, Han XH Tags: Acta Pharmacol Sin Source Type: research

Zoledronic Acid Dosing Interval for Metastatic Cancer
To the Editor Dr Himelstein and colleagues found that the use of zoledronic acid every 12 weeks compared with the standard dosing interval of 4 weeks did not result in an increased risk of skeletal events over 2 years in patients with bone metastases. The randomized, open-label clinical trial included 855 patients with breast cancer, 689 with prostate cancer, and 278 with multiple myeloma, broadening the potential applicability of the findings. Although the authors concluded that this longer interval may be an acceptable treatment option, we would like to raise a concern about applying the study results to patients with mu...
Source: JAMA - April 11, 2017 Category: Journals (General) Source Type: research

Zoledronic Acid Dosing Interval for Metastatic Cancer
To the Editor A noninferiority trial investigated the optimal schedule for zoledronic acid in patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with at least 1 bone metastasis, demonstrating similar efficacy with less frequent administration. This finding is important because some adverse effects of bisphosphonates are related to cumulative drug exposure. Furthermore, life expectancy of these patients is increasing, and therefore they are treated for longer periods. (Source: JAMA)
Source: JAMA - April 11, 2017 Category: Journals (General) Source Type: research

Zoledronic Acid Dosing Interval for Metastatic Cancer —Reply
In Reply Dr Tanimoto and colleagues raise a valid point about the apparent survival advantage of monthly zoledronic acid, but not other bisphosphonates, when added to conventional treatment for patients with untreated multiple myeloma. The CALGB 70604 (Alliance) trial was not restricted to untreated vs previously treated patients with multiple myeloma nor was it powered to address a survival end point. Hence, given the potential survival benefit of zoledronic acid in first-line treatment of multiple myeloma, clinicians and patients with multiple myeloma may want to have a more focused discussion concerning the optimal dosi...
Source: JAMA - April 11, 2017 Category: Journals (General) Source Type: research

A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors.
Authors: Manfredi M, Mergoni G, Goldoni M, Salvagni S, Merigo E, Meleti M, Vescovi P Abstract BACKGROUND: The aim of this study was to evaluate the incidence and the risk factors of osteonecrosis of the jaw (ONJ) in a group of patients treated with zoledronic acid (ZA) for bone metastases from solid tumors and enrolled in a preventive dental program. METHODS: This 5-year retrospective longitudinal study included all consecutive oncological patients who underwent at least one infusion with ZA between 2004 and 2011 for bone metastases due to solid neoplasms. RESULTS: Of the 156 patients enrolled in the study,...
Source: Medicina Oral, Patologia Oral y Cirugia Bucal - April 10, 2017 Category: ENT & OMF Tags: Med Oral Patol Oral Cir Bucal Source Type: research

Radiodensitometric study for evaluation of bone mineral density around dental implants after zoledronic acid treatment in ovariectomized rats.
Authors: Dikicier S, Dikicier E, Karacayli U, Erguder B Abstract BACKGROUND: The purpose of this study was to evaluate the effects of intravenous zoledronic acid applied systemically on osseointegration of dental implants and the surrounding bone mineral density (BMD) in the ovariectomized rats. MATERIAL AND METHODS: 36 rats were divided into three groups: control (CTRL), ovariectomy (OVX), and ovariectomy-zoledronic acid (OVX/ZOL). The rats in the CTRL group underwent sham surgery, while rats in OVX and OVX / ZOL group underwent ovariectomy. After 12 weeks, rats from OVX / ZOL were injected with 0.04 mg/kg ZOL...
Source: Medicina Oral, Patologia Oral y Cirugia Bucal - April 10, 2017 Category: ENT & OMF Tags: Med Oral Patol Oral Cir Bucal Source Type: research

Bisphosphonate-Related Osteonecrosis and Metastasis Within the Same Site of the Jaw: Expected for Multiple Myeloma, But Unusual for Breast Cancer
I want to congratulate Corsi et  al1 for the case report in which they presented a patient with breast cancer treated with zoledronic acid for skeletal metastasis in which a clinical diagnosis of bisphosphonate-related osteonecrosis of the jaw (BP-related ONJ) was made and histologic examination of the resected mandibular segment disclosed synchronous osteonecrosis and breast cancer metastasis. As the authors stated, this metastatic presentation in the mandibular region is unusual for breast cancer because bone metastases in breast cancer commonly occur in the spine, pelvis, ribs, and sternum. (Source: Journal of Oral...
Source: Journal of Oral and Maxillofacial Surgery - April 3, 2017 Category: ENT & OMF Authors: Kadri Altundag Tags: Letter to the editor Source Type: research

Inflammatory Markers and Frailty in Long ‐Term Care Residents
ObjectivesTo determine whether proinflammatory biomarkers are associated with frailty assessed according to functional status, mobility, mental health, and falls over 24 months. DesignSecondary analysis of a 2‐year double‐blind clinical trial for osteoporosis. SettingNursing homes and assisted living facilities. ParticipantsWomen aged 65 and older with osteoporosis in long‐term care (LTC) (N = 178). MeasurementsBaseline serum concentrations of proinflammatory cytokines and soluble receptors (high sensitivity C‐reactive protein (hs‐CRP), tumor necrosis factor alpha (TNFα) and its two receptors (TNFα‐...
Source: Journal of the American Geriatrics Society - March 21, 2017 Category: Geriatrics Authors: Gabrielle A. Langmann, Subashan Perera, Mary A. Ferchak, David A. Nace, Neil M. Resnick, Susan L. Greenspan Tags: Clinical Investigation Source Type: research

Zoledronic acid improves bone histomorphometry in a murine model of Rett syndrome
Rett syndrome (RTT) is a neurodevelopmental disorder predominately affecting young females, caused by deficiency of the global transcriptional protein methyl CpG binding protein 2 (MeCP2). Osteoblasts express MeCP2 and girls with RTT experience early onset osteoporosis, decreased bone mass and an increased fracture risk. There is no defined treatment for osteoporosis associated with RTT. The present study evaluated the effects of zoledronic acid (ZA), a third generation nitrogen-containing bisphosphonate with primarily anti-osteoclastic activity, in a mouse model of MeCP2 deficiency. (Source: Bone)
Source: Bone - March 18, 2017 Category: Orthopaedics Authors: Jay R. Shapiro, Adele L. Boskey, Stephen B. Doty, Lyudmila Lukashova, Mary E. Blue Tags: Full Length Article Source Type: research

Zoledronic Acid Treatment in Primary Bone Marrow Edema Syndrome.
Authors: Flores-Robles BJ, Sanz-Sanz J, Sanabria-Sanchinel AA, Huntley-Pascual D, Andréu Sánchez JL, Campos Esteban J, Blanco R, Merino-Argumanez C, Espinosa-Malpartida M, Ramos-Giráldez MC, Godoy-Tundidor H, Jiménez-Palop MM, Barbadillo Mateos C, Villa-Alcázar LF, Isasi CM, Mulero JB Abstract Primary bone marrow edema syndrome (BMES) is characterized by the combination of joint pain and distinctive magnetic resonance imaging changes. It has been suggested that the use of bisphosphonate drugs reduce symptom severity. Our objective was to review cases of patients diagnosed with BME...
Source: Journal of Pain and Palliative Care Pharmacotherapy - March 15, 2017 Category: Palliative Care Tags: J Pain Palliat Care Pharmacother Source Type: research

Bone Pain Induced by Multiple Myeloma Is Reduced by Targeting V-ATPase and ASIC3
In this study, we studied MMBP in an intratibial mouse xenograft model that employs JJN3 human multiple myeloma cells. In this model, mice develop MMBP associated in bone with increased sprouting of calcitonin gene-related peptide-positive (CGRP+) sensory nerves and in dorsal root ganglia (DRG) with upregulation of phosphorylated ERK1/2 (pERK1/2) and pCREB, two molecular indicators of neuron excitation. We found that JJN3 cells expressed a vacuolar proton pump (V-ATPase) that induced an acidic bone microenvironment. Inhibition of JJN3-colonized bone acidification by a single injection of the selective V-ATPase inhibitor, b...
Source: Cancer Research - March 14, 2017 Category: Cancer & Oncology Authors: Masahiro Hiasa, Tatsuo Okui, Yohance M. Allette, Matthew S. Ripsch, Ge-Hong Sun-Wada, Hiroki Wakabayashi, G. David Roodman, Fletcher A. White, Toshiyuki Yoneda Tags: Microenvironment and Immunology Source Type: research

A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [ 18 F]FMAU-Positron Emission Tomography Imaging of Bone Metastases in Prostate Cancer
ConclusionsFMAU tracer was able to detect bone metastases in CRPC patients but uptake was highly variable in bony lesions. Zoledronic acid did not produce an appreciable change in scans. Future investigations of FMAU tracer as a marker of early response in CRPC is recommended. (Source: Molecular Imaging and Biology)
Source: Molecular Imaging and Biology - March 13, 2017 Category: Molecular Biology Source Type: research

Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24 ‐month Clinical Study
ObjectiveThis randomized, double‐blind, placebo‐controlled study assessed the necessity of early intervention, safety and efficacy of intravenous zoledronic acid 5 mg/year in East China women with newly diagnosed osteoporosis at high risk of fracture during a 24‐month treatment period. MethodsSubjects (57 [52–62] years old) were randomized 3:2 to zoledronic acid versus placebo (randomized at baseline, zoledronic acid [175 cases], placebo‐zoledronic acid [110 cases]). The bone mineral density of the lumbar spine and total hip was measured every 6 months with the use of dual‐energy X‐ray absorptiometry. Ser...
Source: Orthopaedic Surgery - March 9, 2017 Category: Orthopaedics Authors: Bo ‐cheng Liang, Zhen‐yu Shi, Bo Wang, Peng Wu, Ling‐cheng Kong, Jian‐liang Yao, Chun‐wen Li, Xiao‐lin Shi Tags: CLINICAL ARTICLE Source Type: research

Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients
Conclusion Although ZA did not improve OS in patients with MM; it continued to be useful to reduce skeletal events, and thus improve better quality of life for patients. Micro-Abstract To assess whether prolonged use of zoledronic acid (ZA; 4 years) improves outcome in multiple myeloma patients, we performed a clinical trial to compare the effect of 48 and 24 months of treatment. A total of 170 patients were randomly assigned to the 2 groups in the trial. Overall survival was not improved, however, the ZA group showed a reduced number of skeletal events. Thus, we suggest that ZA should be considered to be used for longer d...
Source: Clinical Lymphoma Myeloma and Leukemia - March 9, 2017 Category: Cancer & Oncology Source Type: research

Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan
ConclusionAlthough zoledronic acid is dominated by alendronate, the incremental QALY is quite small in extent. Considering the advantage of annual zoledronic acid treatment in compliance and persistence, zoledronic acid may be a cost-effective treatment option compared to alendronate. (Source: Osteoporosis International)
Source: Osteoporosis International - March 6, 2017 Category: Orthopaedics Source Type: research

Abstract P3-04-14: Zoledronic acid sensitized breast cancer cells to fulvestrant via ERK/FOXO3a/HIF-1 {alpha} inhibition through nuclear FOXO3a translocation
This abstract was not presented at the symposium. (Source: Cancer Research)
Source: Cancer Research - March 2, 2017 Category: Cancer & Oncology Authors: X Jia, G Liu, Z Shen, Z Shao Tags: Poster Session Abstracts Source Type: research

Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid
(Source: The Breast Journal)
Source: The Breast Journal - March 1, 2017 Category: Cancer & Oncology Authors: Claudia Omarini, Maria E. Filieri, Roberta Depenni, Giulia Grizzi, Stefano Cascinu, Federico Piacentini Tags: Letter to the Editor Source Type: research

Zoledronic acid for neonatal subcutaneous fat necrosis
Key Clinical Message Subcutaneous fat necrosis (SFN) in infants producing severe hypercalcemia is a life‐threatening emergency. Pathophysiology may include enhanced gastrointestinal calcium absorption and bone resorption. We treated an infant with SFN and serum calcium of 15 mg/dL with prednisolone and low‐dose zoledronic acid. Serum calcium promptly normalized without rebound hypocalcemia, and redosing of zoledronic acid was not necessary. Subcutaneous fat necrosis (SFN) in infants producing severe hypercalcemia is a life‐threatening emergency. Pathophysiology may include enhanced gastrointestinal calcium...
Source: Clinical Case Reports - March 1, 2017 Category: Journals (General) Authors: Jeremy A. Di Bari, Jennifer A. Nead, Scott J. Schurman Tags: Case Report Source Type: research